Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

被引：29
|
作者：
Attar, Eyal C. [1 ]
Amrein, Philip C. [1 ]
Fraser, James W. [1 ]
Fathi, Amir T. [1 ]
McAfee, Steven [1 ]
Wadleigh, Martha [2 ]
DeAngelo, Daniel J. [2 ]
Steensma, David P. [2 ]
Stone, Richard M. [2 ]
Foster, Julia [1 ]
Neuberg, Donna [3 ]
Ballen, Karen K. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Ctr Leukaemia, Boston, MA USA
[2] Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷 / 09期
关键词：
Bortezomib and lenalidomide in MDS and AML; ACUTE MYELOGENOUS LEUKEMIA; INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; STEM-CELLS; KAPPA-B; THERAPY; RISK; CYTARABINE; INDUCTION; DELETION;
D O I：
10.1016/j.leukres.2013.05.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We conducted a phase I dose escalation study to determine the maximal tolerated dose of bortezomib that could be combined with standard dose lenalidomide in patients with MDS or AML. Treatment consisted of bortezomib (IV) on Days 1, 4, 8, and 11 and lenalidomide 10 mg daily (PO) days 1-21 in 28 day cycles for up to 9 cycles. 23 patients (14 MDS/CMML, 9 AML) were enrolled. The maximally tested dose of bortezomib, 1.3 mg/m(2), was tolerable in this regimen. Responses were seen in patients with MDS and AML. Further testing of this regimen is planned. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1016 / 1020
页数：5
相关论文
共 50 条
  • [31] Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry.
    George, Tracy
    Patel, Jay L.
    Abedi, Mehrdad
    Cogle, Christopher R.
    Erba, Harry Paul
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Kiselev, Pavel
    Komrokji, Rami S.
    Louis, Chrystal Ursula
    Maciejewski, Jaroslaw P.
    Nifenecker, Melissa
    Pollyea, Daniel Aaron
    Roboz, Gail J.
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Steensma, David P.
    Thompson, Michael A.
    Foucar, Kathryn
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia
    Huetter, Marie-Luise
    Fiedler, Walter
    Kuendgen, Andrea
    Krauter, Juergen
    von Lilienfeld-Toal, Marie
    Kayser, Sabine
    Rafler, Heidi
    Doehner, Hartmut
    Schlenk, Richard F.
    [J]. BLOOD, 2010, 116 (21) : 1350 - 1351
  • [33] A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)
    Skikne, B. S.
    Ward, M. R.
    Nasser, A.
    Aukerman, L.
    Garcia-Manero, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?
    Platzbecker, U.
    Germing, U.
    [J]. LEUKEMIA, 2013, 27 (09) : 1813 - 1819
  • [35] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    [J]. BLOOD, 1999, 94 (10) : 234B - 234B
  • [36] REDIFINING MONOSOMY 20 BY MOLECULAR CYTOGENETICS IN 1.0 MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA (MDS/AML) PATIENTS
    Bernasconi, P.
    Dambruoso, I.
    Boni, M.
    Zappatore, R.
    Cavigliano, P. M.
    Giardini, I.
    Calatroni, S.
    Rocca, B.
    Caresana, M.
    Tarantino, P.
    Lazzarino, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 273 - 273
  • [37] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
    Griffiths, Elizabeth A.
    Brady, William E.
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Bashaw, Heather L.
    Sperrazza, Jill
    Wetzler, Meir
    Wang, Eunice S.
    [J]. LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
  • [38] Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Sallman, David A.
    DeZern, Amy
    Sweet, Kendra
    Steensma, David P.
    Cluzeau, Thomas
    Sekeres, Mikkael
    Garcia-Manero, Guillermo
    Roboz, Gail
    McLemore, Amy
    McGraw, Kathy
    Puskas, John
    Zhang, Ling
    Bhagat, Chirag
    Graber, Armin
    Al Ali, Najla H.
    Padron, Eric
    Tell, Roger
    Lancet, Jeffrey E.
    Fenaux, Pierre
    List, Alan F.
    Komrokji, Rami S.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [39] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Skikne, Barry
    Cogle, Christopher R.
    Ning, Yuhong
    MacBeth, Kyle J.
    Laille, Eric
    Ward, M. Renee
    [J]. BLOOD, 2009, 114 (22) : 53 - 53
  • [40] A phase I study of idarubicin dose escalation with amifostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes
    Garcia-Manero, G
    Faderl, S
    Giles, F
    Thomas, D
    Cortes, J
    O'Brien, S
    Davis, J
    Kantarjian, HM
    Estey, E
    [J]. HAEMATOLOGICA, 2002, 87 (08) : 804 - 807
12345